Clinical trial · Interventional
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Neuroblastoma (NB) is characterized by its wide heterogeneity in clinical presentation and evolution. Recent retrospective studies have revealed by CGH-array that the overall genomic pattern is an important prognostic marker which might be taken into account for treatment stratification. This protocol deals with a prospective analysis of the genomic profile established by CGH-array on the tumor samples obtained at the diagnosis of all the patients with NB in France, to obtain genomic profiles and being able to determine their prognostic impact in the various protocols of treatment. The objective of this study will be a better therapeutic stratification in the future trials, studies or protocols of treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prospective cohort
- description
- Experimental arm, prospective cohort
- interventionNames
- Procedure: Blood sampling
Primary outcomes (1)
- measure
- Progression-Free survival
- timeFrame
- 3 years
- description
- Time between patient diagnosis and tumoral progression or relapse or death. Correlation with the genomic profile established by CGH-array.
Secondary outcomes (2)
- measure
- Progression at metastatic location-Free survival
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Neuroblastoma or Ganglioneuroblastoma defined by INSS criteria (Brodeur et al. 1993) 2. Age \< 18 years 3. Availability of tumoral sample obtained at diagnosis, prior chemotherapy with tumor cell content ≥ 60% 4. Inclusion in 4 months following the diagnosis 5. All patients treated in French centers (SFCE) for Neuroblastic tumour, including those participate in national or international protocols. 7\. Written informed consent 8. Patients with French Social Security in compliance with the French law relating to biomedical research. Exclusion Criteria: 1. Chemotherapy or radiotherapy before taking tumour samples 2. Refusal of the parents or the legal representatives
References
Publications (0)
Data not yet available